HC Wainwright & Co. Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $64
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Rhythm Pharmaceuticals with a Buy rating and set a price target of $64.
September 18, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Rhythm Pharmaceuticals with a Buy rating and a price target of $64, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $64 by HC Wainwright & Co. suggests a positive sentiment towards Rhythm Pharmaceuticals. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100